CSPC Pharmaceutical Group (FRA:CVGU) Research & Development: €719 Mil (TTM As of Dec. 2025)


FRA:CVGU CSPC Pharmaceutical Group Ltd FRA:CVGU
88 GF Score
Price €2.58
GF Value €2.52
! 4 Warning Signs
View Full Analysis

What is CSPC Pharmaceutical Group Research & Development?

CSPC Pharmaceutical Group FRA:CVGU -5.84% 88 Research & Development is €719 Mil as of Dec. 2025. GuruFocus rates FRA:CVGU with a GF Score™ of 88/100 and a GF Value™ of €2.52. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. CSPC Pharmaceutical Group's Research & Development for the three months ended in Dec. 2025 was €197 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €719 Mil.

CSPC Pharmaceutical Group  (FRA:CVGU) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

CSPC Pharmaceutical Group Research & Development Related Terms

CSPC Pharmaceutical Group Research & Development Historical Data

* Premium members only.

The historical data trend for CSPC Pharmaceutical Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CSPC Pharmaceutical Group Research & Development Chart

CSPC Pharmaceutical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 476.95 539.79 620.35 680.85 704.32

CSPC Pharmaceutical Group Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 166.16 166.68 179.69 196.88 176.05
FRA:CVGU
88GF Score
CSPC Pharmaceutical Group Ltd FRA:CVGU
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CSPC Pharmaceutical Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €719 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €719 Mil mean?
CSPC Pharmaceutical Group (FRA:CVGU) has a Research & Development of €719 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on CSPC Pharmaceutical Group and its competitors.
Is CSPC Pharmaceutical Group's Research & Development too high?
CSPC Pharmaceutical Group's current Research & Development is €719 Mil. Overall, CSPC Pharmaceutical Group has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does CSPC Pharmaceutical Group's Research & Development compare to LLY and JNJ?
CSPC Pharmaceutical Group's Research & Development of €719 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on CSPC Pharmaceutical Group and its competitors. CSPC Pharmaceutical Group's current Research & Development is €719 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSPC Pharmaceutical Group stock overvalued right now?
CSPC Pharmaceutical Group (FRA:CVGU) has a current Research & Development of €719 Mil. The stock's GF Value™ is €2.52, compared to a current price of €2.58 — trading 2.4% above its estimated fair value. The current Research & Development is €719 Mil. CSPC Pharmaceutical Group's overall GF Score™ is 88/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For CSPC Pharmaceutical Group (FRA:CVGU), the current Research & Development is €719 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CSPC Pharmaceutical Group (FRA:CVGU) Overvalued in 2026?

Based on GuruFocus' analysis, CSPC Pharmaceutical Group stock appears to be overvalued. The current stock price of €2.58 is trading 2.4% above its estimated GF Value™ of €2.52.

Key valuation signals for FRA:CVGU:

  • Research & Development: €719 Mil
  • GF Value™: €2.52 vs. price of €2.58 (2.4% above fair value)
  • GF Score™: 88/100 with 4 warning signs

No single metric tells the full story. See the FRA:CVGU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CSPC Pharmaceutical Group Business Description

Address No.896 Zhongshandong Street, Gaoxin District, Hebei Province, Shijiazhuang, CHN, 050035
CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.
88GF Score

Get the complete analysis for FRA:CVGU

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.58
Price
€2.52
GF Value